Method for prognosing and diagnosing tumors

Granted patent in Europe (EP3494228B1)

published in the United States (US20200181713A1)

and worldwide(WO2018024609A2)

Priority date: August 3rd, 2016

Consortium:

CBmed logo   

Method for prognosing and diagnosing tumors

Background

Eukaryotic translation initiation factors (eIFs) are crucial in the initiation of protein translation. Protein biosynthesis can directly target the translation of specific mRNA and foster cell viability, invasion, formation of metastasis and tumor proliferation. Deregulated protein biosynthesis contributes to carcinogenesis and the progression of cancer.

eIFs have been described to be aberrantly expressed in various tumor entities, showing association with tumor development and cancer progression.

Influence of eukaryotic translation initiation factor 6 (eIF6) on non-small lung cancer development and progression.

Influence of eukaryotic translation initiation factor 6 (eIF6) on non-small lung cancer development and progression.

Gantenbein et al., 2018, EJC

Clinical need

This patent covers methods for prognosing and diagnosing hepatocellular carcinoma (HCC) and lymphoma. HCC is the most common type of primary liver cancer and the third leading cause of cancer-related deaths worldwide. Furthermore, hepatitis C and hepatitis B infection can induce HCC.

Lymphoma is a group of blood cell tumors that develop from lymphocytes. The diffuse large B-cell lymphoma is most frequent in adults, and 40% of patients are not cured due to the heterogeneity of the disease.

Our solution

We investigated the relevance of eIFs in HCC and lymphoma and analyzed their prognostic properties. We showed the relationship between the aberrant expression of various eIFs and patient outcome. The established method includes the diagnosis of non-virus-related HCC, hepatitis C- and hepatitis B-associated HCC by determining the expression level of at least one eIF in patient samples.

elF expression in liver metastases of CC and RC compared to NNLT. (A) Representative pictures of
immunohistochemical stainings from liver metasteses of primary CRC. Scale bars: 200
um and 50um. (B) Densitometric analyses of
immunohistochemical staining from various elF subunits in liver metasteses of primary CC (CC- Met) and RC (RC-Met) compared to
non-neoplastic liver tissues (NNLT).

Effects & benefits

Given the poor methods prognosing HCC available so far, we provide a better prognosis and diagnosis with eIF biomarkers for non-virus related and virus related HCCs.

By determining the expression levels of eIFs in lymphoma affected patients, a better prognosis for the patient and decision support for the treatment can be made. High-risk patients can be supervised after treatment to prevent a disease relapse.

Are you interested in a collaboration on this patent? Get in contact with our Business Development Team:

Julia Schmidt
Business Development Manager

The COMET Center CBmed is funded within COMET – Competence Centers for Excellent Technologies by the Federal Ministry of Climate Action, Environment, Energy, Mobility, Innovation and Technology (BMK), the Federal Ministry for Digital and Economic Affairs (BMDW), Land Steiermark (Styrian Business Promotion Agency – SFG) and Land Wien (Vienna Business Agency – WAW). The COMET program is executed by the Austrian Research Promotion Agency (FFG).

CBmed GmbH Center for Biomarker Research in Medicine
Stiftingtalstrasse 5   8010 Graz   Austria   office@cbmed.at   +43 316 385 28801

PRESS CORNER     CONTACT     IMPRINT     PRIVACY

Font Resize
Contrast